Effective clinical intervention strategies for coronavirus disease 2019 (COVID-19) are
urgently needed. Although several clinical trials have evaluated use of convalescent plasma …

In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …

Despite various attempts to treat severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2)-infected patients with COVID-19 convalescent plasmas, neither appropriate …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Neutralizing antibodies for the treatment of COVID-19 | Nature Biomedical Engineering Skip to
main content Thank you for visiting nature.com. You are using a browser version with limited …

The use of therapeutic neutralizing antibodies against SARS-CoV-2 infection has been
highly effective. However, there remain few practical antibodies against viruses that are …

Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …

While there are various attempts to administer COVID-19-convalescent plasmas to SARS-
CoV-2-infected patients, neither appropriate approach nor clinical utility has been …

There is an urgent need for effective therapeutic interventions against SARS-CoV-2,
including new variants that continue to arise. Neutralizing monoclonal antibodies have …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in
December 2019 and spread rapidly. The purpose of this study was to compare neutralizing …